The development of skeletal muscle in vertebrate embryos is controlled by a transcriptional cascade involving the four myogenic regulatory factors. In the somites of the mouse embryo the order of expression is thought to be Myf5, Myogenin, Mrf4 and MyoD. We have re-examined the expression pattern of Mrf4 and show that in the hypaxial domain of thoracic somites (the somitic bud) Mrf4 expression precedes or is contemporaneous with that of Myf5, suggesting that this transcription factor plays a hitherto unsuspected role in myogenesis. q
Results and discussion
The development and differentiation of skeletal muscle are controlled by a transcriptional cascade in which the four myogenic regulatory factors, Myf5, Myogenin, Mrf4 and MyoD, play key roles. In mouse embryos Myf5 is first expressed in the epaxial domain of the somites at 8.0 dpc, followed by Myogenin (8.5 dpc), Mrf4 (9.0 dpc) and MyoD (10.5 dpc) (reviewed: Buckingham, 1992) . Mrf4 downregulates by 12.0 dpc and then there is a second phase of expression beginning at 14.5 dpc that persists into adulthood Hinterberger et al., 1991) . Mutational analyses indicate that Myf5 initiates and co-ordinates the myogenic cascade, that Myogenin controls terminal differentiation and that MyoD plays a particular role in limb muscle development (reviewed: Arnold and Braun, 2000) . The function of Mrf4 remains unclear because all three mutations constructed to inactivate it also affect control of Myf5 expression (Olson et al., 1996; Summerbell et al., 2000) .
We have recently initiated a comprehensive transgenic study of the transcriptional regulation of the linked genes Mrf4 and Myf5 using BAC constructs (Carvajal et al., 2001) .
While much of the data was in accord with previously published results on Mrf4 expression derived from radioactive in situ hybridization to tissue sections and RT-PCR analyses Hinterberger et al., 1991) , there were significant differences. Our new data, obtained using digoxigenin whole-mount in situ hybridization, reveal novel aspects of Mrf4 expression which suggest that it has previously unsuspected functions during embryogenesis.
The earliest reliable Mrf4 expression is detected from ss16-19 (Fig. 1A) , trailing Myf5 by 12-15 somites (18-24 h, see Summerbell et al., 2000) . It is a little earlier than previous comparisons Hinterberger et al., 1991; Ott et al., 1991) but our procedure has higher sensitivity (see Section 2). The labelled cells appear to be localized in the dorsal half of the somite but not in or adjacent to the dermomyotomal lip (DML). Expression then progresses caudally in the normal sequence for somitic markers. By ss21-23 embryos typically express in 11-14 rostral somites with only six to ten negative caudal somites (Fig. 1B) . During the time taken to make four somites the wave of expression has advanced by nine somites, and there is therefore not a constant time interval between the birth of the somite and the initiation of expression. We occasionally see labelled cells in relatively caudal somites (Fig. 1C ), but sporadic anachronistic expression is typical of the MRFs (e.g. Smith et al., 1994) . By ss22-25 the pattern of expression changes dramatically ( pectedly, it precedes expression in the dorsal domain of the same somite. Furthermore, when comparing the timing of onset of expression to that of Myf5 at the same location, Mrf4 appears before or contemporaneous with Myf5. Mrf4 expresses in a previously undescribed location 24 h earlier than expected and at the same time (^1.5 h) as Myf5. The precocious expression in the hypaxial domain is at its most marked towards the end of laying down of thoracic somites (Fig. 1E) . By ss25-29 (Fig. 1F, 10 .0 dpc) the digoxigenin data start to converge on the previously published pattern of expression. Somite 26 is the start of lumbar segmentation, and lumbo-sacral and tail somites appear to lack the novel ventral Mrf4 domain. Subsequent development is as previously described (Fig. 1G ). Transverse sections confirm . Again Mrf4 appears initially in several somites at much the same time rather than sequentially. Epaxial expression (yellow arrow) lags by four somites. (E) ss25: the ventral expression domain rapidly encroaches on the more recently born somites and is already on in So II (red arrow). The early expressing cells seem to be in the dermomyotome of the somitic bud rather than in the myotome and present a different morphology to those of the more dorsal domain (yellow arrow). (F) ss28: in lumbo-sacral somites there is no obvious somitic bud expression domain (red arrow). Meanwhile, in the older thoracic somites there is now Mrf4 expression across the full dorso-ventral extent of the myotome and cells in the hypaxial domain are becoming spindle shaped (green arrow). (G) ss33 (10.0 dpc): the pattern matches that previously described with epaxial (yellow arrow) preceding hypaxial (red arrow) expression in lumbo-sacral and tail somites. Note that throughout this early phase Mrf4 expresses only in somites.
the location of Mrf4 within the somites (Fig. 2) . The novel pattern and timing were verified on two divergent mouse strains (see Section 2).
It has generally been held that Mrf4 acts relatively late in the myogenic cascade and this is probably the case for most sites of myogenesis. However, our data show that in the somitic bud of ventral thoracic somites Mrf4 is activated early, certainly no later than Myf5, and probably earlier (Fig. 3) , and both clearly express before MyoD (see Fig.  1B ,C, Borycki et al., 1999; Fig. 2E, Chen et al., 2001 ). This activation occurs in cells that have not overtly differentiated in the dermomyotome of the somitic bud, whereas generally the gene is turned on only in cells that have the characteristic spindle shaped morphology of differentiated muscle cells. Myf5 and MyoD contain a conserved protein motif that endows them with the ability to remodel chromatin. Myogenin lacks the motif, consistent with the observation that Myogenin is unable to initiate myogenesis (Gerber et al., 1997) . The equivalent motif in Mrf4 can functionally replace that of MyoD (Bergstrom and Tapscott, 2001) . The construction of a clean null allele of Mrf4 will allow analysis of the function of this gene in the somitic bud.
Materials and methods
Whole-mount in situ hybridization was carried out on Cba £ C57(B6) and Parkes mouse embryos using digoxigenin labelled riboprobes as described in Summerbell et al. (2000) . Riboprobes were prepared using T7 RNA polymer- ase on an XbaI linearized 1063 bp (BbrPI-MscI) genomic sub-clone of Myf5 and on a HindIII linearized 352 bp (StuI-StuI) genomic sub-clone of Mrf4. In preliminary experiments we established that the Mrf4 probe had a better signal to noise ratio than the mouse probe used by Bober et al. (1991) ; we did not carry out comparable trials with the rat probe used by Hinterberger et al. (1991) . Sections were cut on a vibratome at 70 mm following agarose embedding. Mouse developmental times are given as somite stages (ss) using the criteria of Spörle and Schughart (1997) . Somites are numbered following the convention of Ordahl (1993) . In So III there is expression in both hypaxial dermomyotome and myotome (red arrows). So XI is a mature somite with labelling throughout epaxial and hypaxial myotome (yellow and red arrows) and with only very limited expression in the somitic bud. (B) Myf5 at ss26: earliest expression is in the epaxial dermomyotome of So I (see Summerbell et al., 2000 for a more complete description). In So II epaxial expression has already spread to myotome (yellow arrow). So X is a mature somite with expression throughout the epaxial and hypaxial myotome (yellow and red arrows). Although in older somites the Mrf4 pattern looks similar to Myf5, side-by-side comparison reveals subtle differences. Myf5 is in general more peripheral, while Mrf4, like Myogenin, is concentrated in the mid-line of the somite. The expression in the myotome may also be less extensive in Mrf4.
